Genentech's Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment

Core Insights - Genentech, a member of the Roche Group, announced positive results from the Phase III IMvigor011 study for Tecentriq as an adjuvant treatment for muscle-invasive bladder cancer patients at risk of recurrence after surgery [1] Group 1 - The study evaluated Tecentriq (atezolizumab) in patients with detectable circulating tumor DNA (ctDNA) [1] - Tecentriq demonstrated a reduction in the risk of death (overall survival, OS) in this ctDNA-guided setting [1]